Sign in
CompletedPhase 4

Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

Key facts

Who runs it
Catholic Kwandong University
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
154 people enrolled
Started
12 Oct 2022
Ended
15 Dec 2023
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
  • quadrivalent influenza vaccine
Record updated
26 March 2024

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • who agreed to receive both bivalent booster COVID-19 vaccine and influenza vaccine
  • Only individuals who had passed at least 3 months after the last confirmation of SARS-CoV-2 infection and/or the third dose of COVID-19 vaccination

Who cannot take part

  • Individuals with a contraindication to any of the vaccine compounds were excluded from the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal is to evaluate the immunogenicity and safety of coadministration of a bivalent BA.4/BA.5-adapted COVID-19 booster vaccine, and influenza vaccine among healthy adults during 2022-23 season.

The 3 groups in the trial

  • C groupTreatment being tested

    Concomitant administration of bivalent mRNA COVID-19 booster and quadrivalent influenza vaccination

    Treatment: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine and quadrivalent influenza vaccine

  • S group (COVID-19 vaccine only)Placebo, for comparison

    separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later

    Treatment: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine

  • S group (influenza vaccine only)Placebo, for comparison

    separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later

    Treatment: quadrivalent influenza vaccine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunogenicity and Safety of Concomitant Administration of Omicron-containing Bivalent COVID-19 Vaccines With Seasonal Influenza Vaccines
Record updated
26 March 2024